Format

Send to

Choose Destination
Can J Cardiol. 2014 Nov;30(11):1460.e3-5. doi: 10.1016/j.cjca.2014.06.015. Epub 2014 Jun 27.

Near fatal ventricular fibrillation in Brugada syndrome despite presence of an implanted implantable cardioverter defibrillator.

Author information

1
Department of Cardiology, Tel-Aviv Sourasky Medical Center, Tel-Aviv and Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel. Electronic address: bblhass@tasmc.health.gov.il.
2
Department of Cardiology, Tel-Aviv Sourasky Medical Center, Tel-Aviv and Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

Abstract

A 38-year-old man with Brugada syndrome and aborted cardiac arrest was treated with quinidine only, based on the results of electrophysiologic drug testing. Six months later, after suffering a vaso-vagal syncope, he opted to receive an implantable cardioverter defibrillator and decided to discontinue quinidine against our recommendation. Sixty-seven months later, he had recurrent ventricular fibrillation that was terminated only by the sixth maximal energy shock delivered by the device (which has the capability to deliver a maximum of 8 shocks). This case suggests the possible risk in only relying on an implantable cardioverter defibrillator in the management of cardiac arrest survivors with Brugada syndrome.

PMID:
25240706
DOI:
10.1016/j.cjca.2014.06.015
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center